Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital Ostrava

About this trial

This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Karnofsky Performance Status ≥ 60

Histologically verified primary cancer disease

MRI findings indicating BM

Disqualifiers

Confirmed hematological malignity

Small-cell (lung) carcinoma

Peracute condition requiring immediate neurosurgical intervention

History of whole-brain radiotherapy (WBRT)

Trial design

Treatments tested in this trial

  • Neoadjuvant Stereotactic Radiotherapy (NaSRT)
  • Postoperative Stereotactic Radiotherapy (SRT)

Treatment groups

260 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University Hospital Ostrava

Lead sponsor

University Hospital Olomouc

Collaborator

Masaryk Memorial Cancer Institute

Collaborator

University Hospital Hradec Kralove

Collaborator